# OnCo record somatic-mutation-theory (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/somatic-mutation-theory/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "somatic-mutation-theory" ;
  schema:name "Somatic mutation theory of cancer"@en ;
  schema:alternateName "SMT"@en, "somatic mutation theory"@en, "gene mutation theory of cancer"@en, "multistep carcinogenesis"@en, "multi-stage theory of carcinogenesis"@en ;
  schema:description "The standard account: cancer begins when a single body cell picks up mutations in the genes that control growth, and its descendants inherit them. It explains why carcinogens are mutagens, why cancer risk runs in some families and why drugs aimed at a mutated gene can work, but it cannot by itself explain why normal tissue full of the same mutations does not become cancer."@en ;
  schema:url <https://onco.cc/terms/somatic-mutation-theory/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Somatic_evolution_in_cancer> ;
  schema:citation <https://doi.org/10.1038/bjc.1954.1>, <https://doi.org/10.1073/pnas.68.4.820>, <https://doi.org/10.1016/0092-8674(90)90186-I>, <https://doi.org/10.1126/science.1260825>, <https://doi.org/10.1126/science.aaa6806>, <https://doi.org/10.1073/pnas.72.9.3585> ;
  onco:tag "theory" ;
  onco:related <https://onco.cc/pathways/theories-of-cancer/>, <https://onco.cc/terms/driver-passenger-model/>, <https://onco.cc/terms/clonal-evolution-theory/>, <https://onco.cc/terms/hallmarks-synthesis/>, <https://onco.cc/terms/tissue-organisation-field-theory/>, <https://onco.cc/terms/epigenetic-progenitor-theory/>, <https://onco.cc/terms/aneuploidy-theory-of-cancer/>, <https://onco.cc/terms/ageing-tissue-field-theory/>, <https://onco.cc/pathways/oncogene-activation-two-hit/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/mutation/>, <https://onco.cc/terms/oncogene/>, <https://onco.cc/terms/tumour-suppressor-gene/>, <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/synthetic-lethality/> ;
  onco:cancers <https://onco.cc/cancers/retinoblastoma/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/cml/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:pathways <https://onco.cc/pathways/oncogene-activation-two-hit/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/mutagenesis-signatures/> ;
  onco:people <https://onco.cc/people/bert-vogelstein/>, <https://onco.cc/people/kenneth-kinzler/>, <https://onco.cc/people/michael-stratton/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/>, <https://onco.cc/key-papers/paper-martincorena-somatic-mutations-normal-skin-science-2015/>, <https://onco.cc/key-papers/paper-levine-p53-gatekeeper-cell-1997/>, <https://onco.cc/key-papers/paper-fearon-cell/>, <https://onco.cc/key-papers/paper-armitage-br-j-cancer/>, <https://onco.cc/key-papers/paper-knudson-proc-natl-acad-sci-u-s-a/>, <https://onco.cc/key-papers/paper-mintz-proc-natl-acad-sci-u-s-a/>, <https://onco.cc/key-papers/paper-tomasetti-science/> .